Dyne Therapeutics, Inc.
Vikram Karnani elected as independent director.
1 source·23/12, 12:36·sec.gov
Dyne Therapeutics announces $328.5 million share offering.
1 source·10/12, 21:24·sec.gov
Dyne secures $50 million loan amendment.
1 source·08/12, 21:10·sec.gov
Positive topline results for z-rostudirsen announced.
1 source·08/12, 11:38·sec.gov
Financial results announcement without major news.
1 source·05/11, 21:21·sec.gov
New director elected; no immediate financial implications.
1 source·02/10, 20:12·sec.gov
FDA grants Breakthrough Therapy Designation for DYNE-251.
1 source·04/08, 11:36·sec.gov
Dyne Therapeutics announces Q2 2025 financial results.
1 source·28/07, 20:16·sec.gov
10-Q form submitted!
1 source·28/07, 20:11·sec.gov
Dyne Therapeutics announces $187 million public offering.
1 source·01/07, 20:42·sec.gov
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
·finviz.com·05/06, 11:43